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Objective: Burkitt lymphoma (BL) is a rare and aggressive form of B-cell lymphoma that is
curable using intensive chemotherapy. Obtaining a complete response (CR) at the end of
induction chemotherapy is a major prognostic factor. This study retrospectively evaluates
the potential impact of 18FDG-PET in the management of children with BL after induction
chemotherapy, and the prognostic performance of the Deauville criteria.
Methods: Nineteen children with BL treated according to the French LMB2001 protocol
between 2005 and 2012 were included. 18FDG-PET and conventional imaging (CI) were per-
formed after induction chemotherapy to confirm CR. 18FDG-PET was interpreted according
to Deauville criteria with follow-up and/or histology as the gold standard.
Results: 18FDG-PET was negative in 15 cases, in agreement with CI in 9/15 cases.The six
discordant cases confirmed to be negative by histology, were considered as true negative
for 18FDG-PET. Negative predictive value (NPV) of CI and 18FDG-PET were 73 and 93%,
respectively. The 5-year progression-free survival (PFS) was significantly higher in patients
with negative 18FDG-PET than those with positive 18FDG-PET (p=0.011).
Conclusion: 18FDG-PET interpreted using Deauville criteria can help confirm CR at the end
of induction chemotherapy, with a prognostic impact on 5-year PFS. Its high NPV could limit
the use of residual mass biopsy. Given the small size of our population, these results need
to be confirmed by future prospective studies on a larger population.
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INTRODUCTION
Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin
lymphoma (NHL). It presents in three distinct clinical forms:
endemic (areas of endemic malaria and early acquisition of
Epstein–Barr virus infection), sporadic, and immunodeficiency-
associated (1). In Europe and North America, BL is mostly spo-
radic and remains rare with an annual incidence of two per
million children under 18 years. Nevertheless, it is the most fre-
quent childhood NHL (30–40%) (2). The most common site
of presentation is the abdomen (60–80%), with rapidly grow-
ing tumor masses, typically in the ileocecal region (3). There-
fore, presenting symptoms include acute abdominal pain, disten-
sion, nausea and vomiting, and gastrointestinal bleeding. Authors
consider bone marrow involvement occurs in roughly 20% of
patients (4).
With the use of intensive multiagent chemotherapy, prognosis
rates of children with BL have significantly improved over the past
25 years. Recent studies have shown that chemotherapy alone is
effective in low, intermediate, and advanced stage disease (5–8)
with 5-year event free survival ranging from 84% in advanced
stage, to 92.5% in low-stage disease. Early response to chemother-
apy was identified as an important prognostic factor by major
United States and European childhood cancer groups, leading to
adapted treatment protocols (7–9).
Positron emission tomography using 18F-fluoro-deoxy-
glucose (18FDG-PET) is a functional imaging modality widely rec-
ommended for staging of FDG-avid lymphomas (10, 11). Accord-
ing to Lugano recommendations (10, 11), 18FDG-PET should
also be used for response assessment in all FDG-avid histolo-
gies using the five-point scale (Deauville criteria). Nevertheless,
while the prognostic value of the 18FDG-PET during treatment
course has been strongly demonstrated in adult Hodgkin and
aggressive lymphomas (12–15), only a few studies were conducted
on 18FDG-PET in children lymphomas especially in BL (16–26).
These studies showed that both nodal and extranodal manifesta-
tions of BL were detectable with this molecular imaging modality
and suggested that 18FDG uptake was reversible after successful
treatment (24–26).
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This latter issue might be of great interest considering the
importance of early response to chemotherapy in the progno-
sis and management of children BL (7–9). The need to achieve
complete response (CR) after induction chemotherapy prior to
deciding on further therapies raises the problem of residual mass
depicted by conventional imaging (CI) after induction chemother-
apy (27). A biopsy of these residual masses is recommended by
most of treatment protocols, but it is invasive and only has value
if positive. Given its potential to differentiate between necrotic or
fibrotic tissue and viable tumor, 18FDG-PET could be an inter-
esting method to characterize residual masses in BL and to avoid
biopsy if negative.
The aim of this retrospective study was to demonstrate the
potential impact of 18FDG-PET in the management of children
with BL after induction chemotherapy. We also evaluated the prog-
nostic performance of the18FDG-PET using the Deauville criteria
in this pediatric type of lymphoma.
MATERIALS AND METHODS
PATIENTS
Nineteen children, diagnosed and treated for histologically proven
sporadic BL, at University Hospital of Nantes between 2005 and
2012 were included. All of them were treated according to the
French LMB 2001 protocol. Eighteen children were evaluated in
first-line treatment. One patient was evaluated in first-line and
during two relapses.
Patients with resected stage I and abdominal stage II dis-
ease received two courses of cyclophosphamide, vincristine,
prednisone, and doxorubicin (COPAD) chemotherapy. Patients
with central nervous system and/or bone marrow involvement
received 7-day, low-dose, prophase cyclophosphamide, vincristine,
and prednisone (COP) therapy. Induction therapy consisted of
two cycles of fractionated COPAD and high-dose methotrexate
(HD-MTX; COPADM). Consolidation included high-dose and
continuous cytarabine with etoposide (CYVE). The other chil-
dren received 7-day low-dose prophase COP. Their treatment
then included two cycles of COPADM, two consolidation cycles
of cytarabine and HD-MTX (CYM), and concluded with one
maintenance phase of COPADM.
Written and informed consent was obtained from each patient
and parents. The local ethics committee approved this study.
Population characteristics are summarized in Table 1.
CONVENTIONAL IMAGING
Response assessment to induction chemotherapy was performed
using CI as recommended in the LMB 2001 protocol. CI consisted,
in addition to clinical examination, of chest X-ray, of contrast
enhanced computed tomography (CT) (Sensation 16, Siemens;
Light Speed VCT, GE Medical systems) and of ultrasound (US).
MRI was performed for head and neck localizations or when
meningeal involvement was suspected. All CI images were eval-
uated based on 1999 international workshop criteria (IWC) (28).
Table 1 | Population and induction treatment characteristics.
Patient no Gender Age at diagnosis Stage Induction treatment received before 18FDG-PET
1 M 6 years III COP – COPADM – COPADM – CYM
2 M 7 years IV COP – COPADM – COPADM – CYVE – CYVE
3 M 6 years II COPAD – COPAD
4 M 12 years IV COP – COPADM – COPADM – CYVE – CYVE
5 M 11 years III COP – COPADM – COPADM – CYM
6 M 14 years IV COP – COPADM – COPADM – CYVE – CYVE
7 M 8 years III COP – COPADM – COPADM – CYM
8 M 12 years IV COP – COPADM – COPADM – CYVE – CYVE
9 M 11 years III COP – COPADM – COPADM – CYM
10 F 9 years III COP – COPADM – COPADM – CYM
11 F 5 years IV COP – COPADM – COPADM – CYVE –CYVE
12 F 17 years II COP – COPADM – COPADM – CYM
13 M 4 years III COP – COPADM – COPADM – CYM
14 M 7 years III COP – COPADM – COPADM – CYM
15 M 3 years IV COP – COPADM – COPADM – CYM
16 M 13 years III COP – COPADM – COPADM – CYM
17 F 14 years IV COP – COPADM – COPADM – CYM
18 M 5 years III COP – COPADM – COPADM – CYM
COP – CYVE –CYVE – RDA EPOCH – BEAM – Autograft
COP – RDHAP – RIVA – RIVA – RIVA – Allograft
19 F 2 years III COP – COPADM – COPADM – CYM
COP, cyclophosphamide, vincristine, and prednisone; COPAD, cyclophosphamide, vincristine, prednisone, and doxorubicin; COPADM,COPADandmethotrexate; CYM,
cytarabine and methotrexate; CYVE, cytarabine and etoposide; RDA EPOCH, rituximab, dexamethasone, adryamicin, etoposide, prednisone, vincristine, cyclophos-
phamide, and doxorubicin; BEAM, carmustine, etoposide, cytarabine, and melphalan; RDHAP, rituximab, cisplatin, cytarabine, and dexamethasone; RIVA, rituximab,
ifosfamide, vincristine, and doxorubicin.
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Reviewing was performed in consensus by two experienced pedi-
atric radiologists blinded to the results of other imaging studies
but with knowledge of available clinical data. According to LMB
2001 protocol recommendations, only patients with CR according
to 1999 IWC criteria were judged to be CI-negative after induction
chemotherapy.
18FDG-PET PROCEDURE AND ANALYSIS
In addition to the standard procedures, all children were examined
with whole-body 18FDG-PET to evaluate response to induction
chemotherapy. 18FDG-PET was performed after two courses of
chemotherapy for stage II BL patients and after four or five courses
for stage III–IV BL patients. In one patient evaluated at initial
staging and during two relapses, 18FDG-PET was performed after
two courses of chemotherapy in first-line and after four courses
at relapses. 18FDG-PET results were not decisional in the patient
management. 18FDG-PET could not be systematically performed
at diagnosis because of the aggressiveness of the disease. Treatment
had to be initiated rapidly and could not be delayed for imaging
purposes.
Whole-body 18FDG-PET was acquired on a Discovery LS
PET/CT imaging system (GE Medical Systems) 60–80 min after
intravenous injection of 5–7 MBq/kg of 18FDG or on a mCT Bio-
graph imaging system (Siemens) after intravenous injection of
3 MBq/kg of 18FDG. Children fasted at least 4 h before 18FDG
injection and blood glucose was controlled prior to the injec-
tion. Images were reconstructed by OSEM iterative reconstruction
algorithm (ordered-subset expectation maximization) with and
without attenuation correction. All 18FDG-PET images were ret-
rospectively reviewed on a dedicated workstation (Positoscope;
Keosys, France).
18FDG-PET was interpreted visually by at least two nuclear
medicine physicians with expertise in lymphoma imaging using
the five-point scale (Deauville criteria), as recently recommended
by Lugano’s Recommendations in Lymphoma (11). 18FDG-PET
was interpreted as follows: 1= no uptake above background,
2= uptake equal to or lower than mediastinum, 3= uptake
between mediastinum and liver uptake, 4= uptake moder-
ately increased compared to the liver, and 5= uptake markedly
increased compared to the liver. Scales 1–3 were considered as
18FDG-PET negative and 4–5 as positive.
VERIFICATION OF FINDINGS
Surgical biopsy or resection was systematically performed in cases
of residual mass on CI. To create a local standard of reference
(SOR), all staging examinations, histopathology of biopsies and
surgical specimens, and clinical data including the serial follow-
up examinations were used for verification of the lesion status.
Finally, the results of CI and 18FDG-PET were verified by an
interdisciplinary tumor board.
STATISTICS
Conventional imaging and 18FDG-PET results were compared to
the status of the disease determined by SOR and classified as true
positive or negative, and false positive or negative allowing deter-
mination of sensitivity (Se), specificity (Sp), positive predictive
value (PPV), or negative predictive value (NPV).
The end point used to evaluate prognosis impact of 18FDG-PET
was progression-free survival (PFS), defined as the time of diag-
nosis to disease progression, relapse, or death whatever the cause.
Survival curves were calculated using Kaplan and Meier analysis.
Differences between groups were analyzed using the Breslow test.
RESULTS
Nineteen children (5 female, 14 male) with histologically proven
BL were included in this study. The median age was 9 years, and
ranged from 2 to 17 years. All children were HIV-negative. A total
of 21 18FDG-PET were performed in addition to CI to confirm
remission after the induction of chemotherapy. Population follow-
up and imaging results are summarized in Table 2. Ten children
(52%) did not reach CR on CI after induction chemotherapy. All
residual masses were either resected or biopsied before therapeutic
modification.
CI AND 18FDG-PET INTERPRETATION
Conventional imaging was negative (CR without residual mass
on CT) in 11 cases. In the 10 other cases, CT was positive and
interpreted as partial response.
According to the gold standard, CI was considered as true neg-
ative in eight cases, false negative in three cases, true positive in












Results TO Results TO Outcome Time (months)
1 CR TN CR TN Alive 100
2 CR TN PR FP Alive 102
3 CR TN CR TN Alive 24
4 CR TN PR FP Alive 80
5 PR TP CR FN Deceased 9
6 PR FP PR FP Alive 86
7 CR TN CR TN Alive 42
8 CR TN CR TN Alive 40
9 PR FP PR FP Alive 56
10 CR TN CR TN Alive 56
11 CR TN PR FP Alive 46
12 CR TN CR TN Alive 57
13 CR TN PR FP Alive 34
14 PR FP PR FP Alive 31
15 CR TN CR TN Alive 34
16 CR TN PR FP Alive 29
17 PR TP PR TP Deceased 4
18 CR FN CR FN Relapse
PR TP CR FN Relapse
CR TN CR TN Alive 35
19 CR TN PR FP Alive 8
CI, conventional imaging; 18FDG-PET, 18FDG-PET interpreted using Deauville cri-
teria; TO, true outcome;TP, true-positive; TN, true-negative; FP, false-positive; FN,
false-negative; CR, complete response; PR, partial response.
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one case and false positive in nine cases. The Se, Sp, PPV, and NPV
of CI were, respectively, of 25, 47, 10, and 73%.
According to the Deauville criteria, 18FDG-PET was negative in
15 cases and positive in 6 cases. 18FDG-PET was in agreement with
CI in 9 of the 15 negative cases. The 6 discordant cases (patients no
2, 4, 11, 13, 16, and 19) presented residual masses without signif-
icant 18FDG uptake. Resection of these lesions revealed no viable
tumor, with necrosis identified on histopathological examination
(Figure 1).
One patient (patient no 18) was considered as a complete
responder after induction treatment on both 18FDG-PET and
CI. This patient experienced an early relapse three months after
the end of treatment. For this analysis, we decided to consider
18FDG-PET and CI results as falsely negative.
18FDG-PET was positive in six cases, in agreement with CI
in four cases. In the four concordant cases, only one (patient
no 17) proved to be a true positive on histopathological analy-
sis, showing residual tumoral cells. In the two discordant cases
(patients no 5 and 18 at first relapse), an early progression was
confirmed by follow-up and 18FDG-PET was considered as true
positive (Figure 2).
According to the gold standard, 18FDG-PET was considered as
true negative in 14 cases, false negative in 1 case, true positive in 3
cases, and false positive in 3 cases.
The Se, Sp, PPV, and NPV values of 18FDG-PET and CI were,
respectively, 75, 82, 50, and 93 versus 25, 47, 10, and 73%. No
significant difference was observed.
An overview of the diagnostic values of CI and 18FDG-PET is
shown in Table 3.
PREDICTION OF PROGRESSION-FREE SURVIVAL
Median follow-up of patients was 45 months (3–100 months).
Of the 18 patients, one relapsed within 3 months and two died
after a median delay of 4 months due to lymphoma progression.
Except for the false-negative exam outlined above (patient no 18),
neither progression nor relapse was observed in patients in the
18FDG-PET negative group.
The Kaplan–Meier survival curves for 5-year PFS according to
18FDG-PET are shown in Figure 3.
The 5-year-PFS was significantly higher among patients
with negative 18FDG-PET than those with positive 18FDG-PET
(p= 0.011). Ninety-three percent (14/15) of patients with score
1, 2, or 3 on Deauville criteria did not experience relapse whereas
50% (3/6) of patients with score 4–5 relapsed or died.
The Kaplan–Meyer survival curves showed no significant dif-
ference in PFS among patients with a positive or negative CI
(p= 0.356) (Figure 4).
DISCUSSION
The few studies previously performed on pediatric lymphomas
patients (16–22) demonstrated a good NPV of 18FDG-PET per-
formed during treatment, with values ranging from 85 to 100%
suggesting biopsy can be avoided if 18FDG-PET was negative. The
recent pediatric study by Furth et al. (17) was conducted on 16
pediatric NHL patients and showed an overall NPV of 85.7%, ris-
ing to 100% when considering only BL (n= 7). Similarly, studies
dedicated to pediatric BL by Karantanis et al. (23) and Riad et al.
(25) reported a 100% NPV of 18FDG-PET after chemotherapy
despite residual masses detected on CI. More recently, Carrillo-
Cruz et al. analyzed the role of 18FDG-PET at the end of treatment
using Deauville criteria. In this heterogeneous study including 13
children and 19 adults and different treatment schemes, the NPV
of 18FDG-PET reached 100% (27). Our results are consistent with
these data and strengthen the literature on a homogeneous popu-
lation of pediatric BL, in which all residual lesions were biopsied or
resected. Indeed, the NPV of 18FDG-PET was higher than 90 ver-
sus 75% for CI. NPV would have reached 100% if we did not decide
to classify patient no 18 as FN (relapse 3 month after chemother-
apy) despite the fact that he reached CR on both 18FDG-PET
and CI, meaning no residual mass was detected. Considering our
patients with residual masses detected by CI at the end of induction
therapy without significant 18FDG uptake, none have experienced
relapse during follow-up. These results suggest that in children
BL, biopsy, or surgical resection of residual lesions depicted by CI
FIGURE 1 |Thirteen-year-old boy with stage III Burkitt’s lymphoma. (A,B) 18FDG-PET and MRI at diagnosis showing oropharynx tumor. (C,D) Negative
18FDG-PET but residual disease on MRI after chemotherapy. Biopsy of the residual mass was negative.
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FIGURE 2 | Five-year-old boy with stage IV Burkitt’s lymphoma at relapse. (A) 18FDG-PET after induction chemotherapy showing a nodular uptake on
spleen whereas CI was negative. (B) 18FDG-PET 12 weeks later, showing disease progression.
after induction chemotherapy can be avoided when 18FDG-PET
is negative.
As expected, considering the nature of 18FDG, most of the avail-
able studies have shown a high false positive rate, leading to a weak
PPV. In the Bakhshi et al. study (22), PPV was 41.2% with only
7 patients considered as true positive on 17 positive 18FDG-PET
scans. Riad et al. (25) described false-positive 18FDG uptake in
four of 28 pediatric patients with abdominal BL. In these stud-
ies, abnormal 18FDG uptake was variously defined: uptake greater
than background activity in surrounding tissue (19, 23, 24), or the
mediastinal blood pool activity (17) or IHP criteria (18) for refer-
ence. In our study, 18FDG-PET images were interpreted with the
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Table 3 | Overview of diagnostic values obtained for 18FDG-PET and CI.





CI 1 3 8 9 25 47 10 73
18FDG-PET 3 1 14 3 75 82 50 93
CI, conventional imaging; 18FDG-PET, 18FDG-PET interpreted using Deauville crite-
ria; TP, true-positive; TN, true-negative; FP, false-positive; FN, false-negative; PPV,
positive predictive value; NPV, negative predictive value.
FIGURE 3 | Kaplan–Meier survival graphs show 5-year PFS according
to negative and positive post-induction chemotherapy 18FDG-PET
using the Deauville criteria.
current consensual set of criteria recently recommended by the
“Lugano recommendations” (10, 11). We only reported three false
positive results related to benign inflammatory processes detected
by histopathological examination. If the use of Deauville criteria
slightly improves PPV compared to previously described criteria,
the PPV remained poor. The PPV of CI is lower in our study than
in previously published reports (18, 19, 22). This lower CI PPV
can be easily explained: because surgical biopsy or resection was
systematically performed in cases of residual masses on CI, only
patients with CR according to 1999 IWC criteria (28) were judged
to be CI-negative. In other studies, CR and/or unconfirmed com-
plete responders (i.e., with residual masses on CI) were considered
to be CI-negative. However, PPV remained poor according to each
modality, and biopsy remained essential in 18FDG-PET and CI
positive cases.
Recent studies in adult NHL (29) and HL (30) reported high-
prognostic value of interim 18FDG-PET (after two or four courses
of chemotherapy). These kinds of results were not described by any
previous studies of pediatric NHL. Furth et al. (17) revealed no
significant difference in PFS neither for interim CI, nor for 18FDG-
PET, nor for semi-quantitative analysis using delta SUVmax in 18
children with lymphomas including 7 BL. In this study, 18FDG-
PET was performed after two cycles of chemotherapy regardless of
the therapeutic scheme or stage of disease, and 18FDG-PET were
interpreted visually using IHP criteria. In the Bakhshi et al. study
FIGURE 4 | Kaplan–Meier survival graphs show 5-year PFS according
to negative and positive post-induction chemotherapy CI results.
(22), response at interim 18FDG-PET or CI did not predict PFS
or overall survival in 34 patients with non-lymphoblastic lym-
phomas including 28 B-cell lymphomas. In Carrillo-Cruz’s study
(27), the Deauville criteria (score ≥4 as positive) did not allow to
predict outcome accurately in a heterogeneous population of BL
when quantitated at the end of treatment. On the contrary, in our
study, the use of Deauville criteria (score≥4 as positive) improved
specificity and PPV and 18FDG-PET was predictive of outcome
(p= 0.011) when performed in an earlier setting (after induction
chemotherapy).
A very recent study on adult diffuse large B-cell lymphoma,
showed that if visual analysis can be employed reliably, compu-
tation of semi-quantitative analysis (∆SUVmax) leads to better
outcome prediction and better reproducibility among observers
(29) in interim 18FDG-PET (after two and/or four courses of
chemotherapy). In the Carrillo-Cruz study (27), NPV reached
100% when ∆SUVmax was <66% of the initial value at the end
of treatment but the prognosis value of the semi-quantitative
analysis was not studied. Unfortunately, as our study was ret-
rospective, we were unable to complete our data by semi-
quantitative analysis for two reasons: unavailable baseline 18FDG-
PET for some of our patients with very aggressive disease
and media-storage degradation for patients included from 2005
to 2008.
CONCLUSION
Our study confirms that 18FDG-PET’s very high NPV could
limit the use of biopsy of residual masses in sporadic pedi-
atric BL. Our results also suggest that 18FDG-PET interpreted
using Deauville criteria can help confirm early CR at the end of
induction chemotherapy with prognostic impact on 5-year PFS.
However, considering the poor PPV, biopsy remains essential to
characterize 18FDG-PET positive residual masses. Nevertheless,
given the small size of our study population and the rarity of
this lymphoma, future prospective studies on a larger population
of children, probably as part of a multicenter study, are highly
warranted.
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